Similarly from what was seen for breast cancer, the combination KIR-HLA showed stronger effect than either KIR or HLA isolated, suggesting the role of KIR-HLA combinations for the risk to develop this disease (Naumova et al., 2007; Al Omar et al., 2010; Giebel et al., 2014). Here, KIR3DL1 is linked to breast carcinoma.